Retatrutide: Triple Agonist Peptide for Weight Loss

Retatrutide (LY3437943) is Eli Lilly's triple receptor agonist in advanced clinical development, targeting the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors simultaneously. By combining the appetite-suppressing benefits of GLP-1 agonism, the metabolic-enhancing effects of GIP agonism, and the energy expenditure-increasing effects of glucagon receptor activation, retatrutide has produced weight loss outcomes exceeding any previously studied pharmaceutical compound. Phase 2 trial data showed mean weight loss of 24% over 48 weeks at the highest dose — approaching the results of bariatric surgery.

The Triple Agonism Concept

GLP-1 and GIP dual agonism (as in tirzepatide) has already shown superiority over GLP-1 alone. Retatrutide adds glucagon receptor agonism to this combination. Glucagon is classically known as GLP-1's counterpart — it raises blood glucose by stimulating hepatic glucose production. However, glucagon receptor activation also increases energy expenditure through thermogenesis in brown adipose tissue and enhances fat oxidation in the liver. The challenge in developing glucagon-inclusive agents is balancing these metabolic benefits against glucagon's hyperglycemic effect. Retatrutide achieves this balance by pairing sufficient GLP-1 and GIP agonism to counteract glucagon-driven hyperglycemia while retaining its metabolic benefits.

Phase 2 Clinical Trial Results

The Phase 2 GZGI study (published in NEJM, 2023) evaluated retatrutide at doses of 1, 4, 8, and 12 mg weekly in adults with obesity. The 12 mg group achieved a mean weight loss of 24.2% at 48 weeks, with approximately one-quarter of participants achieving weight loss exceeding 30%. These results are remarkable: most participants lost weight continuously throughout the 48-week period, suggesting the dose had not yet reached a plateau at study end. Reductions in visceral fat, liver fat, and waist circumference were proportionally large. Blood pressure, lipids, and glycemic markers all improved substantially. A Phase 3 program (TRIUMPH) is underway with results expected in 2025-2026.

Side Effect Profile

The side effect profile of retatrutide mirrors the GLP-1 agonist class: nausea, vomiting, diarrhea, and constipation are the predominant adverse effects, with frequency and severity increasing at higher doses. The 12 mg dose group had higher rates of GI side effects compared to lower doses, though discontinuation due to side effects was modest (less than 10%). A notable finding was that retatrutide also produced small increases in heart rate (approximately 4-5 bpm), a known class effect of glucagon receptor activation, which requires monitoring in individuals with cardiac conditions.

Retatrutide vs. Tirzepatide

Retatrutide's 24% mean weight loss compares to tirzepatide's 20-22% at maximum doses in similar populations. Whether this additional 2-4% represents clinically meaningful superiority will be determined in Phase 3 comparison data. The additional glucagon component in retatrutide provides energy expenditure benefits that GIP alone does not, which may explain part of the efficacy advantage. The glucagon-related heart rate increase and potential metabolic effects also distinguish retatrutide's risk-benefit profile from tirzepatide.

Implications for Obesity Treatment

If retatrutide's Phase 3 results confirm Phase 2 findings, it could establish a new benchmark for pharmaceutical obesity treatment, approaching surgical outcomes (30%+ weight loss) non-invasively for a meaningful subset of patients. This would represent a transformation in how severe obesity is managed, potentially reducing the indications for bariatric surgery for many individuals. The drug is expected to seek FDA approval for obesity and type 2 diabetes in the 2026-2027 timeframe.

FAQ

When will Retatrutide be available? Retatrutide is currently in Phase 3 clinical trials. If results confirm Phase 2 efficacy and the submission and review process proceeds normally, FDA approval could come in 2026-2027. This timeline could accelerate or slow depending on trial results and regulatory interactions.

Will Retatrutide replace tirzepatide? Retatrutide and tirzepatide will likely serve different patient populations. Retatrutide's superior weight loss efficacy may make it preferred for patients needing maximum weight reduction, while tirzepatide's more established track record and eventually lower cost (as patents expire) may make it preferred for broader use. Both compounds will likely coexist as part of an expanding therapeutic toolkit.

What does the glucagon agonism component add over just GLP-1/GIP? Glucagon receptor activation increases basal metabolic rate through hepatic and thermogenic mechanisms, increases fatty acid oxidation, and may reduce liver fat more rapidly than GLP-1/GIP alone. These effects complement appetite suppression by attacking stored energy from the expenditure side. The net effect is a more complete metabolic reset that produces greater weight loss than appetite suppression alone.

Track your supplements in Optimize.